Arca
Skip to content
Tools
Tools

CLCN2: Chloride channel protein 2

Voltage-gated and osmosensitive chloride channel.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CLCN2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Lubiprostone

Phase 30

    Phase 21

    • Cobiprostone

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      LubiprostoneApprovedMallinckrodtSmall moleculeOpenerChloride channel protein 2 opener3
      CobiprostonePhase 2MallinckrodtSmall moleculeActivatorChloride channel protein 2 activator0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
      Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal CancerLubiprostonePhase 2Not yet recruitingSun Yat-sen UniversityFeb 12, 2026
      Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit ConstipationLubiprostonePhase 3RecruitingThird Military Medical UniversityDec 11, 2025
      Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced ConstipationLubiprostone—RecruitingBioDelivery Sciences InternationalOct 25, 2018

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Leukoencephalopathy with mild cerebellar ataxia and white matter edema
      0.81
      Familial hyperaldosteronism type II
      0.75
      Constipation disorder
      0.59
      Bowel dysfunction
      0.35
      Intelligence
      0.31
      Non-alcoholic fatty liver
      0.26
      Chronic constipation
      0.24
      Hereditary disease
      0.20

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1628478, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P51788, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.